FDA to decide on Ionis's zilganersen for Alexander disease by Sept. 22
The priority review rests on a pivotal trial that showed a 33.3% gait-speed benefit over control, a result that would make zilganersen the first approved treatment for the disease.
Executive Summary
- The FDA is due to decide by September 22, 2026 whether to approve the first treatment ever for Alexander disease, a rare and often fatal neurological condition with no disease-modifying options today.
- The application rests on a pivotal trial that already showed the drug slowed gait decline against control, with the benefit also carrying through most secondary measures of function and symptom burden.
- The application arrives with a a set of FDA designations reserved for treatments addressing serious unmet need, positioning it for a compressed review timeline relative to standard applications.
- No other company is running a late-stage program against this same drug target in this disease, leaving the FDA's read on this single dataset as the only near-term determinant of whether patients gain a treatment option.
The filing and the stake
The FDA accepted Ionis Pharmaceuticals, Inc.'s New Drug Application for zilganersen under priority review and set a target action date of September 22, 2026. Alexander disease is a rare, progressive neurological condition with no approved disease-modifying treatment; Ionis chief executive Brett Monia called it "a devastating condition, commonly resulting in progressive motor and cognitive dysfunction, loss of independence" and said approval would make zilganersen "the first and only treatment for Alexander disease". The drug is an antisense oligonucleotide that degrades GFAP messenger RNA through RNase H recruitment, targeting the mutated protein believed to drive the disease. IonisIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority ReviewMar 23, 2026
The pivotal result
The NDA is built on results from a randomized, double-blind, controlled Phase 3 trial (NCT04849741) that enrolled 54 patients across the United States, the United Kingdom, Canada, Italy, Australia, Israel, Japan and the Netherlands. In that trial, the 50 mg dose of zilganersen showed a statistically significant and clinically meaningful stabilization on the primary endpoint, percent change from baseline on the 10-Meter Walk Test, at week 61, with a least-square mean difference of 33.3% versus control (p=0.0412). Results across secondary and exploratory measures of adaptive function, communication, gastrointestinal symptoms, sleep and seizures also favored the drug, and the company reported favorable safety and tolerability. IonisIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority ReviewMar 23, 2026
Designation history
Zilganersen carries Breakthrough Therapy, Orphan Drug, and Rare Pediatric Disease designations from the FDA, along with Orphan Drug status from the European Medicines Agency granted in 2019. Priority review itself signals that the FDA views the application as offering an improvement over existing options for a serious condition, compressing the standard ten-month review to six months. Results have not yet posted to the trial's public registry record, so the topline figures disclosed by the company remain the operative evidence pending the agency's own review. IonisIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority ReviewMar 23, 2026
Trial timeline
The trial's primary completion date moved three times over its run, from February 2024 to March 2025, then September 2025, before settling at August 22, 2025. Enrollment peaked at 73 patients before settling at 54 when the study moved to Active, not recruiting status in July 2025. The trial's overall completion date is not due until September 2029, reflecting the multi-year natural-history and long-term follow-up built into the design even as the primary endpoint has already read out. NCT04849741A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD)NCT04849741
The competitive field
No other clinical-stage program targets GFAP in Alexander disease; the only other trial-level activity against this target sits within Ionis's own portfolio. Nearby programs against other RNA-targeting antisense mechanisms, such as Biogen's tofersen for ALS and GlaxoSmithKline's bepirovirsen for hepatitis B, share the modality but address different targets and diseases, and offer no direct efficacy benchmark for this indication. With no validated disease-modifying mechanism ever established in Alexander disease, the FDA's review turns on whether the observed gait-speed effect and its supporting secondary endpoints hold up as durable, decision-grade evidence in a single 54-patient study.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.